IN 2013, the FDA warned that olmesartan can cause sprue-like enteropathy. The FDA approved changes to the label of this drug to include this concern.
Contra-indicated in patients with diabetes.
- TRADE NAMES: Benicar (Sankyo); Olmetec (Daiichi Sankyo)
- INDICATIONS: Hypertension
- SYNONYM: Olmesartan medoxomil
- CLASS: Angiotensin receptor antagonist (blocker), Antihypertensive
- HALF-LIFE: ~13 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
ACE inhibitors, Adrenergic neurone blockers, Aldesleukin, Aliskiren, Alprostadil, Amifostine, Antihypertensives, Antipsychotics, Anxiolytics and hypnotics, Baclofen, Beta blockers, Calcium channel blockers, Clonidine, Colesevelam, Corticosteroids, Cyclosporine, Diazoxide, Diuretics, Eltrombopag, Eplerenone, Estrogens, General anesthetics, Heparins, Hydralazine, Levodopa, Lithium, MAO inhibitors, Methyldopa, Methylphenidate, Minoxidil, Moxisylyte, Moxonidine, Nitrates, Nitroprusside, NSAIDs, Pentoxifylline, Phosphodiesterase 5 inhibitors, Potassium salts, Quinine, Rituximab, Tacrolimus, Tizanidine, Tolvaptan, Trimethoprim - PREGNANCY: category C in first trimester; category D in second and third trimesters
- See adverse reactions attributed to class:
FETAL TOXICITY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 01/14/2026
